2023 phase II SBIR - Intuitive Bio, 75N93023C00007
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is forecasting a new requirement for a Phase II Small Business Innovation Research contract with Intuitive BioScience, Inc., the Phase I awardee under contract 75N93023C00007, with an estimated solicitation release date of September 1, 2026 and an estimated award date of July 1, 2027. The effort continues development and validation of an HIV diagnostic that differentiates HIV infection from vaccine-induced seropositivity, building on Phase I work under PHS 2023-1, NIAID Topic 115, which established platform optimization and controls and produced a peer-reviewed publication. The source describes promising results for sensitive detection of low HIV amounts as a point-of-care test, and the forecast is set aside for total small business under NAICS 541715.
The estimated award value range is $1.5 million to $3.0 million. Points of contact are Callie Prassinos, Contracting Officer, at callie.prassinos@nih.gov or +1 240-669-5155, and Milton Maciel at milton.maciel@nih.gov.
Forecast text
This request is for an invitation to submit a Small Business Innovation Research (SBIR) Phase II contract proposal to Intuitive BioScience, Inc. previously provided significant value to the Government through its Phase I SBIR contract award (75N93023C00007) under PHS 2023-1, NIAID Topic 115, "Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity." During Phase I of the contract, the company established the foundational technical parameters for the test, including platform optimization and controls and even published their results in aper reviewed journal (https://doi.org/10.1016/j.vesic.2025.100084). This innovative test for HIV diagnostics has significant potential, with promising results for sensitive detection of low amounts of HIV as a POC test. The Government's investment in Phase I would not be fully realized if the company is not provided the opportunity to compete for a Phase II award. A Phase II contract would support continued development and validation of this promising diagnostic technology, building directly on the successful Phase I outcomes. Advancing this work is in the best interest of the Government and the American people, as it aligns with the NIH mission to improve the diagnosis of infectious diseases.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast